Literature DB >> 6362631

The bone-resorbing activities in tissue culture of lipopolysaccharides from the bacteria Actinobacillus actinomycetemcomitans, Bacteroides gingivalis and Capnocytophaga ochracea isolated from human mouths.

Y Iino, R M Hopps.   

Abstract

The activities of lipopolysaccharides (LPS) were assessed by measuring the calcium release from mouse calvaria in vitro and compared to that of LPS from Salmonella typhimurium. Stimulation of bone resorption was maximal at an LPS concentration of 10 micrograms/ml and at this dose all oral LPS preparations showed similar levels of activity and less than that of LPS from S. typhimurium. Only S. typhimurium LPS and B. gingivalis LPS retained bone-resorbing activity at 0.1 microgram/ml. No bone-resorbing activity was observed against killed bone and histochemical observations of stable acid phosphatase activity indicated both mononuclear and multinuclear cells participating in bone removal. Addition of indomethacin to the culture medium did not inhibit calcium release from the bones by any of the LPS preparations except for that from A. actinomycetemcomitans. Fetal calf serum completely blocked the activities of all the LPS preparations whereas human serum did not inhibit the action of B. gingivalis LPS. Thus this particular LPS could be important in mediating bone loss in chronic periodontitis.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6362631     DOI: 10.1016/0003-9969(84)90043-8

Source DB:  PubMed          Journal:  Arch Oral Biol        ISSN: 0003-9969            Impact factor:   2.633


  35 in total

1.  Studies of the healing of bone grafts, and the incorporation of titanium implants in grafted bone: an experimental animal model.

Authors:  E Liljensten; C Larsson; P Thomsen; G Blomqvist; J M Hirsch; C Wedenberg
Journal:  J Mater Sci Mater Med       Date:  1998-09       Impact factor: 3.896

Review 2.  Bacterially induced bone destruction: mechanisms and misconceptions.

Authors:  S P Nair; S Meghji; M Wilson; K Reddi; P White; B Henderson
Journal:  Infect Immun       Date:  1996-07       Impact factor: 3.441

Review 3.  Inflammatory and immune pathways in the pathogenesis of periodontal disease.

Authors:  Ali Cekici; Alpdogan Kantarci; Hatice Hasturk; Thomas E Van Dyke
Journal:  Periodontol 2000       Date:  2014-02       Impact factor: 7.589

Review 4.  Herpesvirus-bacteria synergistic interaction in periodontitis.

Authors:  Casey Chen; Pinghui Feng; Jørgen Slots
Journal:  Periodontol 2000       Date:  2020-02       Impact factor: 7.589

5.  Production of an interleukin-1 inhibitor by cell line P388D1 murine macrophages stimulated with Haemophilus actinomycetemcomitans lipopolysaccharide.

Authors:  T Nishihara; T Koga; S Hamada
Journal:  Infect Immun       Date:  1988-11       Impact factor: 3.441

Review 6.  Emerging roles of immunostimulatory oral bacteria in periodontitis development.

Authors:  Yizu Jiao; Mizuho Hasegawa; Naohiro Inohara
Journal:  Trends Microbiol       Date:  2014-01-13       Impact factor: 17.079

7.  Characterization of inhibitory effects of suspected periodontopathogens on osteogenesis in vitro.

Authors:  P M Loomer; R P Ellen; H C Tenenbaum
Journal:  Infect Immun       Date:  1995-09       Impact factor: 3.441

8.  Inflammatory cytokine gene expression in human periodontal ligament fibroblasts stimulated with bacterial lipopolysaccharides.

Authors:  Y Yamaji; T Kubota; K Sasaguri; S Sato; Y Suzuki; H Kumada; T Umemoto
Journal:  Infect Immun       Date:  1995-09       Impact factor: 3.441

9.  Inhibition of gingival fibroblast growth by Bacteroides gingivalis.

Authors:  H Larjava; V J Uitto; E Eerola; M Haapasalo
Journal:  Infect Immun       Date:  1987-01       Impact factor: 3.441

10.  Porphyromonas gingivalis induces receptor activator of NF-kappaB ligand expression in osteoblasts through the activator protein 1 pathway.

Authors:  Nobuo Okahashi; Hiroaki Inaba; Ichiro Nakagawa; Taihei Yamamura; Masae Kuboniwa; Koji Nakayama; Shigeyuki Hamada; Atsuo Amano
Journal:  Infect Immun       Date:  2004-03       Impact factor: 3.441

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.